Therapeutic Goods (Exempting monographs of pharmacopoeias) Determination No. 1 of 2011

Overview

The Therapeutic Goods (Exempting monographs in pharmacopoeias) Determination No. 1 of 2011, enacted by the delegate of the Minister for Health and Ageing under section 3C(1) of the Therapeutic Goods Act 1989, aims to address a specific regulatory gap in the national system of controls for therapeutic goods. This Determination exempts certain monographs from the United States Pharmacopeia-National Formulary from being considered as a "standard" for the purposes of the Act. The Therapeutic Goods Administration (TGA), which administers the Act, sought to streamline the regulatory process by aligning with internationally recognised standards while ensuring the quality, safety, efficacy, and timely availability of therapeutic goods. The Determination was developed following public consultation and endorsement by the Therapeutic Goods Committee, and it commenced on the day after its registration on the Federal Register of Legislative Instruments. The policy objective of this Determination is to enhance the regulatory framework by recognising the standards set forth in the United States Pharmacopeia-National Formulary, thereby facilitating the efficient and effective management of therapeutic goods within Australia. The decision to exempt specific monographs from being classified as a "standard" under the Act is intended to reduce unnecessary regulatory burdens and ensure that the TGA can focus on the most critical aspects of therapeutic goods oversight. The Determination's alignment with internationally recognised standards also supports Australia's participation in the global therapeutic goods market, promoting consistency and harmonisation in therapeutic goods regulation.

Scope and Application

The Therapeutic Goods (Exempting Monographs in Pharmacopoeias) Determination No. 1 of 2011 applies to specified monographs in the United States Pharmacopeia-National Formulary, which are deemed not to constitute a "standard" for the purposes of the Therapeutic Goods Act 1989. This Determination was made under the authority provided by section 3C(1) of the Act and is intended to facilitate the regulation of therapeutic goods by excluding certain monographs from the definition of "standard". The scope of the Determination encompasses entities involved in the manufacture, supply, and registration of therapeutic goods in Australia, ensuring that the specified monographs in the United States Pharmacopeia-National Formulary do not interfere with the application of Australian standards for these goods. The jurisdictional reach of this Determination is national, aligning with the broader national system for the regulation of therapeutic goods established by the Act. The Determination does not explicitly state exclusions or exemptions beyond the specified monographs, and its application is not extended or restricted through subordinate instruments.

Key Provisions

The Therapeutic Goods (Exempting monographs in pharmacopoeias) Determination No. 1 of 2011 (the Determination) specifies that certain monographs in the United States Pharmacopeia-National Formulary are exempt from the definition of a "standard" under the Therapeutic Goods Act 1989 (the Act) (section 3C(1)). These monographs, which outline the specifications for identity, strength, quality, purity, packaging, and labelling for substances and dosage forms, do not constitute a "standard" as per the Act's definition. This means that therapeutic goods manufacturers and suppliers can rely on these monographs without needing to adhere to additional regulatory standards imposed by the Therapeutic Goods Administration (TGA). Under the Act, the TGA is responsible for ensuring that therapeutic goods are safe and of high quality. By exempting certain monographs from the standard definition, the Determination allows manufacturers to use these monographs as a reliable guide without additional regulatory burdens. This is particularly beneficial for ensuring that therapeutic goods meet necessary quality and safety standards without unnecessary duplication of efforts. Breaching the provisions of the Determination could lead to significant legal consequences. Manufacturers who fail to comply with the standards outlined in the Act, despite the exemption, may face penalties. These could include fines or other civil or criminal penalties as determined under the Act. The maximum penalties can be severe, reflecting the importance of maintaining high standards for therapeutic goods to protect public health. The Determination aims to streamline regulatory processes by recognising the United States Pharmacopeia-National Formulary as a reliable source of quality and safety standards. By doing so, it helps ensure that therapeutic goods on the market are safe and effective, without imposing unnecessary regulatory constraints on manufacturers. The exemptions provided by the Determination are intended to facilitate compliance with the Act while maintaining rigorous quality and safety standards for therapeutic goods.